Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral therapeutics - Genekam

Drug Profile

Research programme: viral therapeutics - Genekam

Alternative Names: Zika virus therapeutics

Latest Information Update: 29 Aug 2016

At a glance

  • Originator Genekam Biotechnology
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Ebola virus infections; Flavivirus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Zika virus infection

Most Recent Events

  • 19 Aug 2016 Early research in Ebola virus infections in Germany (unspecified route)
  • 19 Aug 2016 Early research in Flavivirus infections in Germany (unspecified route)
  • 19 Aug 2016 Early research in Influenza virus infections in Germany (unspecified route)

Development Overview

Introduction

Genekam is developing therapeutic molecules for the treatment of various viral diseases including zika virus infection, influenza, Ebola, Middle East respiratory syndrome coronavirus (MERS) and mosquito borne flaviviruses. Currently, detection of Zika virus is the only option available for the prevention of the infection. The Zika virus infection generally causes mild or no symptoms. The symptoms if caused, are a very mild form of dengue fever. Zika can also spread from a pregnant woman to her fetus, which may result in microcephaly in the newborn. Early research of the therapeutic molecule for the Zika virus infection is underway in Germany.

Key Development Milestones

In August 2016, Genekam annouced that the therapeutic molecule developed against Zika virus, inhibits the Zika virus infection and presumably is non-toxic. Additional studies are planned for the therapeutic molecule prior to human trials [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    J05A (Direct acting antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Ebola virus infections - - Research Germany unspecified / unspecified 19 Aug 2016
Flavivirus infections - - Research Germany unspecified / unspecified 19 Aug 2016
Influenza virus infections - - Research Germany unspecified / unspecified 19 Aug 2016
Middle East respiratory syndrome coronavirus - - Research Germany unspecified / unspecified 19 Aug 2016
Zika virus infection - - Research Germany unspecified / unspecified 19 Aug 2016

Commercial Information

Involved Organisations

Organisation Involvement Countries
Genekam Biotechnology Originator Germany
Genekam Biotechnology Owner Germany

Development History

Event Date Update Type Comment
19 Aug 2016 Phase Change Early research in Ebola virus infections in Germany (unspecified route) [1] Updated 29 Aug 2016
19 Aug 2016 Phase Change Early research in Flavivirus infections in Germany (unspecified route) [1] Updated 29 Aug 2016
19 Aug 2016 Phase Change Early research in Influenza virus infections in Germany (unspecified route) [1] Updated 29 Aug 2016
19 Aug 2016 Phase Change Early research in Middle East respiratory syndrome coronavirus in Germany (unspecified route) [1] Updated 29 Aug 2016
19 Aug 2016 Phase Change Early research in Zika virus infection in Germany (unspecified route) [1] Updated 29 Aug 2016

References

  1. World Innovation and Hope: First Therapeutic Molecule Candidate of Genekam Against Zika Viruses.

    Media Release
Back to top